Key Takeaways
- CRWV shares declined 3.4% to close at $83.53, touching an intraday bottom of $79.46, while trading volume registered 20% below typical levels
- Analysts hold a Moderate Buy rating with a consensus price target of $135, though some projections reach as high as $250
- Reports of Meta exploring the AI cloud computing space have triggered investor anxiety about future competitive pressures facing CoreWeave
- Company insiders have offloaded more than $3 billion in CRWV shares over the last three months, primarily through pre-scheduled tax withholding arrangements
- The company’s Q1 results disappointed expectations with EPS of -$1.40 versus consensus of -$1.17, despite revenue climbing 111.6% annually to $2.08 billion
CoreWeave (CRWV) shares retreated 3.4% during Tuesday’s trading session, settling at $83.53 following an intraday descent to $79.46. The previous session had seen the stock close at $86.46.
CoreWeave, Inc. Class A Common Stock, CRWV
Trading activity reached approximately 23 million shares, falling roughly 20% short of the stock’s typical daily volume — indicating the downturn wasn’t fueled by frantic liquidation.
CRWV has gained 26% since the beginning of the year but remains down 41% over the trailing twelve months, trading significantly beneath its 50-day moving average of $106.86.
Tuesday’s weakness emerged amid mounting investor anxiety centered on two key issues: Meta’s reported exploration of AI infrastructure services, and substantial equity sales by company insiders.
According to a Bloomberg article, Meta is evaluating plans to offer AI computing resources and general computing capacity to third-party clients — a strategy that would position the social media giant as a direct rival to CoreWeave’s primary business model.
Rosenblatt maintained its Buy recommendation with a $250 price objective, contending the Meta threat is exaggerated. Both Wolfe Research and Evercore ISI reaffirmed Outperform ratings with $150 targets.
Executive Stock Sales Draw Investor Scrutiny
Insider transactions have become a focal point for market watchers. Over the previous 90 days, company insiders have divested more than $3 billion in CRWV equity.
Most recently, General Counsel Kristen J. McVeety disposed of 22 shares valued at $1,889 on July 6, pursuant to a Rule 10b5-1 trading arrangement established in May 2025.
Prior to that, insider Brian Venturo sold 76,912 shares on July 1 at an average price of $86.99, generating approximately $6.69 million in proceeds. This transaction reduced his holdings by 21%.
Insider Brannin McBee unloaded 56,707 shares on June 30 at $95.69 per share, totaling roughly $5.43 million — representing a 14.9% reduction in his ownership stake.
Both transactions were conducted through pre-established Rule 10b5-1 trading plans designed to satisfy tax liabilities on vesting stock compensation. While this is standard corporate practice, the magnitude of these sales has attracted considerable attention.
Recent Earnings Disappointment Lingers
CoreWeave’s most recent quarterly report, released May 7, failed to bolster investor confidence. The firm reported EPS of -$1.40, falling short of the -$1.17 analyst consensus by $0.23.
Revenue reached $2.08 billion, representing 111.6% year-over-year expansion. While top-line momentum remains robust, the path to profitability appears distant — the company’s net margin currently stands at -25.57%.
Wall Street analysts project full-year EPS of -$4.57 on average.
Despite the earnings shortfall, multiple analysts have suggested the stock’s decline is excessive. BNP Paribas holds the Street’s most optimistic price target at $192, while Cantor Fitzgerald maintains a $167 objective. Wells Fargo lifted its target to $155 in May.
Among 35 analysts tracking the stock, 21 assign it a Buy rating, 12 recommend Hold, and 2 rate it a Sell.
The company operates with a debt-to-equity ratio of 3.68 and maintains a current ratio of merely 0.31 — a financial structure that presents considerable risk alongside its growth narrative.
CoreWeave’s market capitalization ranges between approximately $37 billion and $45 billion, fluctuating with daily trading. The company introduced ARIA, an AI-powered research assistant, earlier this week — though analysts view it as unlikely to significantly impact near-term performance.
